Courtney DiNardo
M.D. Anderson Cancer Center · Abramson Cancer Center at Penn Medicine
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Courtney DiNardo as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:01 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07411586 · Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid LeukemiaM.D. Anderson Cancer Center · active not recruiting · Acute Myeloid Leukemia · principal investigator
- Ph2NCT07032727 · Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway MutationsM.D. Anderson Cancer Center · recruiting · Targeted Therapy, IDH1-Mutated Malignancies, Mutations · principal investigator
- Ph1/Ph2NCT06664879 · ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform TrialM.D. Anderson Cancer Center · active not recruiting · AML · principal investigator
- Ph1NCT06616636 · A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)M.D. Anderson Cancer Center · recruiting · Myelodysplastic Syndrome, Acute Myeloid Leukemia · principal investigator
- Ph1/Ph2NCT06445959 · Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor OlutasidenibM.D. Anderson Cancer Center · recruiting · Mutant IDH1 Inhibitor Olutasidenib · principal investigator
- Ph2NCT06261060 · Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet DisorderM.D. Anderson Cancer Center · recruiting · Familial Platelet Disorder, Hematopoietic · principal investigator
- Ph1/Ph2NCT04874194 · Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1M.D. Anderson Cancer Center · terminated · Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Myeloid Leukemia · principal investigator
- Ph1/Ph2NCT04774393 · Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaM.D. Anderson Cancer Center · recruiting · Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia · principal investigator
- N/ANCT04774744 · Effect of Digital Health Coaching Program on Self-efficacy and Patient Reported Outcomes of Patients With Newly Diagnosed Acute Myeloid Leukemia or Chronic Lymphocytic LeukemiaM.D. Anderson Cancer Center · completed · Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia · principal investigator
- Ph2NCT04493164 · CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeM.D. Anderson Cancer Center · recruiting · Acute Myeloid Leukemia With Gene Mutations, Myelodysplastic Syndrome, Myeloproliferative Neoplasm · principal investigator
- Ph2NCT03683433 · Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene MutationM.D. Anderson Cancer Center · recruiting · Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Chronic Myelomonocytic Leukemia · principal investigator
- Ph1/Ph2NCT03634228 · Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid LeukemiaM.D. Anderson Cancer Center · terminated · Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia · principal investigator
- Ph1/Ph2NCT03471260 · Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic MalignanciesM.D. Anderson Cancer Center · recruiting · Acute Myeloid Leukemia, Hematopoietic and Lymphoid System Neoplasm, Myelodysplastic Syndrome · principal investigator
- Ph2NCT03383575 · Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic SyndromeM.D. Anderson Cancer Center · recruiting · Acute Myeloid Leukemia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia · principal investigator
- Ph1/Ph2NCT03214562 · Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid LeukemiaM.D. Anderson Cancer Center · recruiting · High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia · principal investigator
- Ph1/Ph2NCT03047993 · Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic SyndromeM.D. Anderson Cancer Center · completed · Acute Myeloid Leukemia With Multilineage Dysplasia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells, Blasts 20-30 Percent of Peripheral Blood White Cells · principal investigator
- Ph2NCT02469415 · Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)M.D. Anderson Cancer Center · terminated · Leukemia · principal investigator
- Ph2NCT02302846 · Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) in RemissionM.D. Anderson Cancer Center · terminated · Leukemia · principal investigator
- Ph2NCT02010645 · Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS)M.D. Anderson Cancer Center · terminated · Leukemia · principal investigator
- Ph2NCT01932710 · A Feasibility Study of Prophylactic White Blood Cell TransfusionsM.D. Anderson Cancer Center · completed · Leukemia · principal investigator
- Ph2NCT01893372 · Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)M.D. Anderson Cancer Center · completed · Leukemia · principal investigator
- N/ANCT01385150 · Biomarkers in Blood Samples From Patients With Acute Myeloid LeukemiaEastern Cooperative Oncology Group · completed · Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:01 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Role of targeting ATPases BRG1/BRM in therapy of AMLR01CA291918 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2025 to 2026 · $542,663 awarded in 2026Same name and institution; not confirmed by an ID
- T32 Research Training in Academic Medical OncologyT32CA009666 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2023 to 2026 · $393,627 awarded in 2026Same name and institution; not confirmed by an ID
- Biology and novel therapy of AML expressing somatic or germline mutant RUNX1R01CA255721 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2021 to 2025 · $496,911 awarded in 2025Same name and institution; not confirmed by an ID
- Novel combination therapy for AML expressing mutant RUNX1R01CA262636 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2021 to 2024 · $507,478 awarded in 2024Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Experimental Medicine ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM · fiscal years 2013 to 2026Named on NCT03383575
- Therapeutic targeting of glutamine metabolism in MDSR01CA206210 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Marina Y Konopleva, Stefano Tiziani, Amit K. Verma · fiscal years 2016 to 2020Named on NCT03047993
Most cited trial papers
Clinical-trial papers with this author name in acute myeloid leukemia, ranked by citations from NIH iCite, fetched 2026-11-12 11:01 UTC. The ranking covers the 200 most relevant of 94 PubMed records, and a shared surname and initials can bring in a namesake. All 94 on PubMed
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.N Engl J Med · 20202,533 citationsRCR 110.4
- 1,254 citationsRCR 40.6
- 1,249 citationsRCR 38.4
- Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.Cancer Discov · 2016949 citationsRCR 29.2
- 653 citationsRCR 27.7
- 633 citationsRCR 20.6
- Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.Cancer Discov · 2019480 citationsRCR 15.8
- 318 citationsRCR 12.5
- Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.J Clin Oncol · 2021297 citationsRCR 16.3
- 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.Lancet Haematol · 2020282 citationsRCR 11.3